Revenio Group Corporation, Stock Exchange Release, May 23, 2017 at 16:45
Revenio Group Corporation applies for listing of stock options 2015 A
Revenio Group Corporation will apply for the listing of its series A stock options, complying with its 2015 option scheme, on the Nasdaq Helsinki Ltd as of May 31, 2017.
The total number of the A series stock options under the 2015 option scheme is 50,000. Each option right entitles its holder to subscribe to one (1) Revenio Group Corporation share. Revenio Group Corporation's subsidiary, Done Medical Oy, holds 14,000 series A option rights.
At the moment, the share subscription price under the A series option rights is EUR 25.48 per share. In accordance with the terms and conditions of the option scheme, the subscription price has been reduced by the amount of dividends decided before the share subscription, on the record date of each dividend payment. In accordance with the terms and conditions of the option scheme, the share subscription period for series A option rights will begin on May 31, 2017. The option rights will be freely transferable as from that date. The subscription period will end on May 31, 2019. The subscription place is Nordea Bank Finland Plc's offices in Finland.
The grounds for the granting of the 2015 option rights and the original terms and conditions were published in a stock exchange release on August 10, 2014. The terms and conditions of the option scheme 2015, as well as the approval schedule for share subscriptions under the option rights are available in full on the company's website at www.revenio.fi .
Revenio Group Corporation Board of Directors
For additional information: President & CEO Timo Hildén, tel. +358 40 580 4774 timo.hilden@revenio.fi www.revenio.fi
DISTRIBUTION: Nasdaq Helsinki Ltd Financial Supervisory Authority (FIN-FSA) Principal media www.revenio.fi
The Revenio Group in brief
Revenio is a Finnish, globally operating health technology corporation whose worldwide success is based on a strongly patented intraocular pressure measurement technology. The Revenio Group consists of Icare Finland Oy, Revenio Research Oy and Oscare Medical Oy, in which Revenio holds a 53.5% interest. The common denominators of Revenio's business operations include screening, follow-up and the global need to make cost savings through preventive health care. Revenio seeks vigorous growth in health technology. Revenio aims to develop even more efficient and easily adopted methods for the early-stage detection of diseases with significance for public health. The focus of Revenio's screening technology is on the early detection of glaucoma, osteoporosis, skin cancer and asthma, and the monitoring of these during the treatment process.
In 2016, Revenio Group's net sales totaled MEUR 23.4, with its operating profit for continuing operations standing at 30.1%. Revenio Group Corporation is listed on Nasdaq Helsinki.
